GSK’s Menveo Secures the EC’s Approval to Prevent Invasive Meningococcal Disease
Shots:
- The EC has granted approval to a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) for preventing invasive meningococcal disease (IMD) due to A, C, W & Y bacterial serogroups
- The single-vial presentation is indicated to actively immunize individuals aged 2 years and older, eliminating the need for reconstitution
- The approval was supported by 2 P-IIb clinical evaluations (2017-003692-61 & 2017-003456-23) demonstrating comparable immunogenicity, tolerability, and safety of the vaccine to the existing lyophilized/liquid formulation
Ref: GSK | Image: GSK
Related News:- GSK Reports the CHMP’s Positive Opinion of Menveo Vaccine Against Invasive Meningococcal Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
